Abstract: The present disclosure belongs to the field of energy materials, and relates to a preparation method of a solid electrolyte, in particular to a method for forming a membrane by using an electrolyte to activate a porous powder material prepared by in-situ polymerization of a polymer on the surfaces of cellulose nanocrystals, and then hot-pressing. According to the technical solution of the present disclosure, cellulose nanocrystals are used as templates, the powder material with a porous structure is prepared by in-situ polymerization growth of the polymer on the surfaces of the cellulose nanocrystals, a small amount of electrolyte is used to activate the powder, and the solid electrolyte is prepared by hot-pressing membrane formation. The solid electrolyte prepared by the present disclosure has excellent electrochemical performance and mechanical performance, and a broad application prospect.

Abstract: The present disclosure belongs to the field of energy materials, and relates to a preparation method of a solid electrolyte, in particular to a method for forming a membrane by using an electrolyte to activate a porous powder material prepared by in-situ polymerization of a polymer on the surfaces of cellulose nanocrystals, and then hot-pressing. According to the technical solution of the present disclosure, cellulose nanocrystals are used as templates, the powder material with a porous structure is prepared by in-situ polymerization growth of the polymer on the surfaces of the cellulose nanocrystals, a small amount of electrolyte is used to activate the powder, and the solid electrolyte is prepared by hot-pressing membrane formation. The solid electrolyte prepared by the present disclosure has excellent electrochemical performance and mechanical performance, and a broad application prospect.

Abstract: The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.

Abstract: The present invention discloses a traditional Chinese drug consisting of Danshen extract and Sanqi extract, the pharmaceutical composition comprising the above traditional Chinese drug as an active component and the use thereof. The traditional Chinese drug consists of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2). The invention further discloses the effect of the above traditional Chinese drug and the pharmaceutical composition comprising the above traditional Chinese drug as an active component for treating cardiac microcirculation disorder and myocardial damage induced by ischemia/reperfusion.

Abstract: The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.

Abstract: The present invention discloses a traditional Chinese drug consisting of Danshen extract and Sanqi extract, the pharmaceutical composition comprising the above traditional Chinese drug as an active component and the use thereof. The traditional Chinese drug consists of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2). The invention further discloses the effect of the above traditional Chinese drug and the pharmaceutical composition comprising the above traditional Chinese drug as an active component for treating cardiac microcirculation disorder and myocardial damage induced by ischemia/reperfusion.